The earnings call reflects a positive outlook with significant progress on the lead product candidate INO-3107 and financial discipline, though challenges remain with a manufacturing issue and cash runway concerns.

Company Guidance

During the third quarter of 2024, INOVIO provided guidance on several key metrics, focusing on the advancement of their lead product candidate, INO-3107, and the company's financial health. The company reported a net loss of $25.2 million, or $0.89 per share, which is an improvement compared to the $33.9 million loss, or $1.52 per share, from the same quarter in 2023. Operating expenses were reduced by 24% year-over-year, from $35.9 million to $27.3 million. INOVIO closed the quarter with $84.8 million in cash, cash equivalents, and short-term investments, projecting a cash runway into the third quarter of 2025. The company aims to submit a Biologics License Application (BLA) for INO-3107 by mid-2025 and plans to be launch-ready by the end of that year. They also highlighted the promising safety and efficacy data for INO-3107, indicating a 72% overall response rate in their Phase I/II trial, with 28% of patients requiring no surgical intervention post-treatment.

Progress on Lead Product Candidate INO-3107

Announced additional immunology data supporting the mechanism of action for INO-3107, potential for reducing surgeries in RRP patients, and presented full safety and efficacy data at scientific conferences.

Positive Pre-BLA Meeting with FDA

Held a positive pre-BLA meeting with the FDA for INO-3107, with BLA submission targeted for mid-2025.

Financial Discipline and Reduction in Operating Expenses

Total operating expenses dropped 24% from $35.9 million in Q3 2023 to $27.3 million in Q3 2024. The company has $84.8 million in cash, cash equivalents, and short-term investments.

Market Preparation and Strategic Choices for INO-3107

Developing a go-to-market strategy for INO-3107, including pricing in line with rare disease pricing and planning for a lean and efficient commercial footprint.

---

Inovio Pharmaceuticals (INO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

INO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 04, 2025	2024 (Q4)	-0.92 / -	-1.1	―	―	―
Nov 14, 2024	2024 (Q3)	-1.15 / -0.89	-1.56	42.95% (+0.67)	―
Aug 08, 2024	2024 (Q2)	-1.10 / -1.19	-1.56	23.72% (+0.37)	―
May 13, 2024	2024 (Q1)	-1.01 / -1.31	-1.92	31.77% (+0.61)	―
Mar 06, 2024	2023 (Q4)	-1.19 / -1.10	-2.64	58.33% (+1.54)	―
Nov 09, 2023	2023 (Q3)	-1.52 / -1.56	-1.8	13.33% (+0.24)	―
Aug 09, 2023	2023 (Q2)	-1.74 / -1.56	-5.52	71.74% (+3.96)	―
May 10, 2023	2023 (Q1)	-1.74 / -1.92	-4.32	55.56% (+2.40)	―
Mar 01, 2023	2022 (Q4)	-2.02 / -2.64	-6	56.00% (+3.36)	―
Nov 08, 2022	2022 (Q3)	-3.50 / -1.80	-3.48	48.28% (+1.68)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

INO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 14, 2024	$4.77	$4.26	-10.69%
Aug 08, 2024	$8.71	$8.44	-3.10%
May 13, 2024	$11.36	$11.42	+0.53%
Mar 06, 2024	$9.87	$9.03	-8.51%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---